TSE:4502Pharmaceuticals
Takeda Pharmaceutical (TSE:4502) Is Up 8.5% After Raising FY2025 Guidance And Dividend Outlook – Has The Bull Case Changed?
In January 2026, Takeda Pharmaceutical reported nine‑month results to December 31, 2025, with sales of ¥3.41 trillion and slightly higher net income of ¥216.08 billion versus the prior year, while also raising its full‑year 2025 revenue, profit and EPS guidance.
The company additionally signalled confidence by guiding to a higher full‑year dividend of ¥100 per share, up from ¥98 a year earlier, alongside the upgraded outlook.
We’ll now examine how Takeda’s raised full‑year guidance,...